These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 17143529

  • 21. An abnormal response of retinoblastoma cells (Y-79) to neurotrophins.
    Wagner N, Wagner KD, Sefton M, Rodríguez-Tébar A, Grantyn R.
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1932-9. PubMed ID: 10845619
    [Abstract] [Full Text] [Related]

  • 22. Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice.
    Turner BJ, Murray SS, Piccenna LG, Lopes EC, Kilpatrick TJ, Cheema SS.
    J Neurosci Res; 2004 Oct 15; 78(2):193-9. PubMed ID: 15378612
    [Abstract] [Full Text] [Related]

  • 23. Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines.
    Sigala S, Faraoni I, Botticini D, Paez-Pereda M, Missale C, Bonmassar E, Spano P.
    Clin Cancer Res; 1999 May 15; 5(5):1211-8. PubMed ID: 10353759
    [Abstract] [Full Text] [Related]

  • 24. Rational basis for Trk inhibition therapy for prostate cancer.
    Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT.
    Prostate; 2000 Oct 01; 45(2):140-8. PubMed ID: 11027413
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 26. Role of nerve growth factor and its receptors in non-nervous cancer growth: efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies antityrosine kinase receptor A and antinerve growth factor: an in-vitro and in-vivo study.
    Rende M, Pistilli A, Stabile AM, Terenzi A, Cattaneo A, Ugolini G, Sanna P.
    Anticancer Drugs; 2006 Sep 07; 17(8):929-41. PubMed ID: 16940803
    [Abstract] [Full Text] [Related]

  • 27. Detection of NGF-receptors TrkA and p75NTR in human tumor cell lines and effect of NGF on the growth characteristic of the UT-7/EPO cell line.
    Westphal G, van den Berg-Stein S, Braun K, Knoch TA, Dümmerling M, Langowski J, Debus J, Friedrich E.
    J Exp Clin Cancer Res; 2002 Jun 07; 21(2):255-67. PubMed ID: 12148587
    [Abstract] [Full Text] [Related]

  • 28. p75 and TrkC neurotrophin receptors demonstrate a different immunoreactivity profile in comparison to TrkA and TrkB receptors in human normal pituitary gland and adenomas.
    Assimakopoulou M, Zolota V, Chondrogianni C, Gatzounis G, Varakis J.
    Neuroendocrinology; 2008 Jun 07; 88(2):127-34. PubMed ID: 18319596
    [Abstract] [Full Text] [Related]

  • 29. Nerve growth factor-induced migration of endothelial cells.
    Dollé JP, Rezvan A, Allen FD, Lazarovici P, Lelkes PI.
    J Pharmacol Exp Ther; 2005 Dec 07; 315(3):1220-7. PubMed ID: 16123305
    [Abstract] [Full Text] [Related]

  • 30. Overexpressions of nerve growth factor and its tropomyosin-related kinase A receptor on chordoma cells.
    Park JB, Lee CK, Koh JS, Lee JK, Park EY, Riew KD.
    Spine (Phila Pa 1976); 2007 Aug 15; 32(18):1969-73. PubMed ID: 17700442
    [Abstract] [Full Text] [Related]

  • 31. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
    Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA.
    Clin Cancer Res; 1999 Aug 15; 5(8):2205-12. PubMed ID: 10473107
    [Abstract] [Full Text] [Related]

  • 32. Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase.
    Woronowicz A, Amith SR, De Vusser K, Laroy W, Contreras R, Basta S, Szewczuk MR.
    Glycobiology; 2007 Jan 15; 17(1):10-24. PubMed ID: 16971381
    [Abstract] [Full Text] [Related]

  • 33. Neurotrophin receptor immunoreactivity in the hippocampus of patients with mesial temporal lobe epilepsy.
    Ozbas-Gerçeker F, Gorter JA, Redeker S, Ramkema M, van der Valk P, Baayen JC, Ozgüç M, Saygi S, Soylemezoglu F, Akalin N, Troost D, Aronica E.
    Neuropathol Appl Neurobiol; 2004 Dec 15; 30(6):651-64. PubMed ID: 15541005
    [Abstract] [Full Text] [Related]

  • 34. Resistance to chemotherapy mediated by TrkB in neuroblastomas.
    Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM.
    Cancer Res; 2002 Nov 15; 62(22):6462-6. PubMed ID: 12438236
    [Abstract] [Full Text] [Related]

  • 35. Nerve growth factor and tyrosine kinase A in human salivary adenoid cystic carcinoma: expression patterns and effects on in vitro invasive behavior.
    Wang L, Sun M, Jiang Y, Yang L, Lei D, Lu C, Zhao Y, Zhang P, Yang Y, Li J.
    J Oral Maxillofac Surg; 2006 Apr 15; 64(4):636-41. PubMed ID: 16546643
    [Abstract] [Full Text] [Related]

  • 36. Effect of exogenous neurotrophins on Trk receptor phosphorylation, cell proliferation, and neurotrophin secretion by cells isolated from the human lamina cribrosa.
    Lambert WS, Clark AF, Wordinger RJ.
    Mol Vis; 2004 Apr 19; 10():289-96. PubMed ID: 15105791
    [Abstract] [Full Text] [Related]

  • 37. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma.
    Ødegaard E, Staff AC, Abeler VM, Kopolovic J, Onsrud M, Lazarovici P, Davidson B.
    Hum Pathol; 2007 Jan 19; 38(1):140-6. PubMed ID: 16996570
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.
    J Mol Endocrinol; 2009 May 19; 42(5):429-35. PubMed ID: 19223455
    [Abstract] [Full Text] [Related]

  • 39. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines.
    Pflug BR, Onoda M, Lynch JH, Djakiew D.
    Cancer Res; 1992 Oct 01; 52(19):5403-6. PubMed ID: 1382843
    [Abstract] [Full Text] [Related]

  • 40. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate.
    Dalal R, Djakiew D.
    Mol Cell Endocrinol; 1997 Oct 31; 134(1):15-22. PubMed ID: 9406845
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.